Safety and Immunovirologic Outcomes with Maraviroc Combination Regimens in Patients with a History of Past Treatment Failures and Virologic Resistance in Brazil: An Open-Label, Multicenter Phase 3b Study
Juvêncio José Duailibe Furtado, Lourenia M. Cassoli(Pfizer (United States)), Max Igor Banks Ferreira Lopes(Ministry of Agriculture, Livestock, and Food Supply), Breno Santos(Hospital Nossa Senhora da Conceição), Alcyone Artioli Machado(Childhood Arthritis and Rheumatology Research Alliance), Margareth da Eira(Instituto de Infectologia Emílio Ribas), Dalia Wajsbrot(Pfizer (United States)), Eliana L. Bicudo(Department of STD, AIDS and Viral Hepatitis), David Salomão Lewi(Hospital São Paulo), Maria Patelli Juliani Souza Lima(Hospital e Maternidade Celso Pierro), Marília Santini-Oliveira(Instituto Evandro Chagas), Simon Portsmouth(Pfizer (United States)), José L. de Andrade Neto(Pontifícia Universidade Católica do Paraná), Antônio F.B. Miranda(Governador Celso Ramos Hospital), Unaí Tupinambás(Universidade Federal de Minas Gerais), José Valdez Madruga, Olavo Henrique Munhoz Leite(Faculdade de Medicina do ABC), Rogério de Jesus Pedro(Universidade Estadual de Campinas (UNICAMP)), Eduardo Martins Netto(Universidade Federal da Bahia)
Cited by 5
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
|New England Journal of Medicine|2011|541